Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 8/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174159 | 0.92 | PDGFRA (0.59) | PDGFRAKDRFGFR2SRCTGFBR1 | |
| SCHEMBL29487188 | 0.92 | PDGFRA (0.59) | PDGFRAKDRFGFR2SRCTGFBR1 | |
| SCHEMBL20022397 | 0.91 | HSPB1 (0.47) | PDGFRAKDRFGFR2SRCTGFBR1 | |
| SCHEMBL165288 | 0.88 | PDGFRA (0.52) | PDGFRAKDRFGFR2SRCTGFBR1 | |
| SCHEMBL30697769 | 0.88 | PDGFRA (0.52) | PDGFRAKDRFGFR2SRCTGFBR1 | |
| SCHEMBL5824446 | 0.86 | PDGFRA (0.60) | PDGFRAKDRSRCTGFBR1AXL | |
| SCHEMBL22009936 | 0.86 | PDGFRA (0.56) | PDGFRAKDRFGFR2SRCTGFBR1 | |
| SCHEMBL13936618 | 0.86 | PDGFRA (0.52) | PDGFRAKDRFGFR2SRCTGFBR1 | |
| SCHEMBL29487138 | 0.86 | KDR (0.50) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL22960033 | 0.86 | KDR (0.50) | PDGFRAKDRFGFR2METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099962-A1 | NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF | NANJING NATINEFY PHARMATECH CO., LTD. (CN) | 2018-04-12 | — | — | US | disclosed |
| US-9938274-B1 | Naphthyridine compounds, medical combinations and use thereof | NANJING NATINEFY PHARMATECH CO., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099962-A1 | NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF | NPM1, NEK4, NME1 | PDGFRA 3797/4885KDR 2288/4885FGFR2 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.